Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5.alpha.-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5.alpha.-reductase inhibitor compounds is also contemplated.
CROSS-REFERENCES TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent application Ser. No. 09/530,443, filed on Apr. 28, 2000, now U.S. Pat. No. 6,576,660 B1 which is a 371 and claims priority to International Application No. PCT/US98/23041, filed on Oct. 30, 1998, which claims priority to U.S. Provisional Application Ser. No. 60/063,770, filed on Oct. 31, 1997. This application claims priority to all such previous applications, and such applications are hereby incorporated herein by reference.
This invention provides methods of treating a mammalian subject in need of androgen therapy by orally administering to the subject testosterone, a testosterone ester, or a testosterone precursor in an oil vehicle and by administering to the subject a modulator such as finasteride or dutasteride which increases testosterone bioavailability in the subject.
This invention relates to compositions comprising co-crystals of (-)-gossypol with a C.sub.1-8 carboxylic acid or C.sub.1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (-)-gossypol with a C.sub.1-8 carboxylic acid or C.sub.1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.
This invention relates to compositions comprising co-crystals of (-)-gossypol with a C.sub.1-8 carboxylic acid or C.sub.1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (-)-gossypol with a C.sub.1-8 carboxylic acid or C.sub.1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.
